The Who, What, and Where for SGLT2 Inhibitors in Diabetes
October 22, 2020 | 10:30 AM - 12:30 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
Clinical Practice Session
The Who, What, and Where for SGLT2 Inhibitors in Diabetes
October 22, 2020 | 10:30 AM - 12:30 PM
Location: Live-Streamed
Session Description
Recent clinical trials show sodium-glucose cotransporter 2 (SGLT2) inhibitors have a significant effect on reducing risk of progressive renal decline as well as cardiovascular outcomes. These discoveries are changing the existing clinical protocols and leading to new, more effective interventions to care for patients with diabetes. In this session, experts in the field present the current trial results and discuss their clinical implications.
Learning Objective(s)
- Describe the mechanisms of SGLT2
- Discuss the controversies regarding whom SGLT2 mechanisms may not benefit
- Summarize efficacy data for SGLT2 inhibitors on heart failure and related outcomes, the proposed mechanisms of this benefit, and the heterogeneity of effects on heart failure stratified by underlying diabetic kidney disease
- Explain how potential adverse effects of SGLT2 inhibitors can be managed
- Define strategies to optimize concurrent management of diabetes, kidney diseases, and heart disease
Learning Pathway(s)
- Diabetes and Metabolism
- Chronic Kidney Disease
Moderators
- Ian H. de Boer, MD, MS
- Adeera Levin, MD
Presentations
- Kidney Protection with SGLT2 Inhibitors in Diabetes: Is It for Everyone?
10:30 AM - 11:00 AM
David Cherney, MD, PhD
David Cherney, MD, PhD
Brief Biography – David Cherney, MD, PhD
Following his clinical training in Nephrology, Dr. Cherney completed his PhD in human renal physiology at the Institute of Medical Science, University of Toronto in 2008. He is currently Professor in the Department of Medicine, University of Toronto and a Clinician Scientist at the University Health Network and Mount Sinai Hospitals, where he is director of the Renal Physiology Laboratory. He is supported by the Canadian Institutes of Health Research, the JDRF, the Heart and Stroke Richard Lewar Centre of Excellence, the Heart and Stroke Foundation of Canada and the Banting and Best Diabetes Centre. He is also supported by a Department of Medicine, University of Toronto Merit Award. Dr. Cherney’s research program focuses on physiological factors that initiate renal disease in patients with diabetes, such as renal hyperfiltration and inflammation, and the role of the cardiorenal axis in diabetes. His research group is also involved in early and late phase clinical trials in the cardiorenal-metabolic field, including several primary renal outcome trials in patients with and without diabetes. Dr. Cherney’s research program is closely aligned with his integrated and multidisciplinary cardiac-renal-endocrine clinic at the University Health Network, which maintains a strong emphasis on the prevention of diabetic nephropathy and cardiovascular disease. In 2019, he received the American Society of Nephrology (ASN) Distinguished Researcher Award for outstanding contributions to nephrology. In 2019 he also received the Diabetes Canada/CIHR - Institute of Nutrition Diabetes and Metabolism (INMD) Young Scientist Award.
Kidney Protection with SGLT2 Inhibitors in Diabetes: Is It for Everyone?
October 22, 2020 | 10:30 AM - 11:00 AM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- SGLT2 Inhibition for the Deadly Dyad of Diabetes: Heart Failure and Kidney Disease
11:00 AM - 11:30 AM
Matthew Cavender, MD, MPH
Matthew Cavender, MD, MPH
SGLT2 Inhibition for the Deadly Dyad of Diabetes: Heart Failure and Kidney Disease
October 22, 2020 | 11:00 AM - 11:30 AM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Adverse Effects of SGLT2 Inhibition in Advanced Diabetic Kidney Disease and How to Minimize Them
11:30 AM - 12:00 PM
Meg J. Jardine, MBBS, PhD
Meg J. Jardine, MBBS, PhD
A/Professor Meg Jardine is a Program Head of Innovation & Kidney Research at The George Institute and a practising nephrologist. Her research focus is the improvement of clinical outcomes for people with kidney disease and diabetes. Her interests include the integration of clinical care and research endeavours, and the promotion of learning health system principles to contribute to the efficient delivery. She has experience in the design and conduct of national and international trials and is particularly interested in response-adaptive techniques as a solution to many of the challenges facing nephrology trials.
A/Prof Jardine is an Executive Committee member of the international nephrology guidelines body, KDIGO, and has contributed to Australian CARI guideline development. She contributes to policy setting and implementation through roles such as Board Member of the Kidney Health Initiative, a public-private collaboration of the American Society of Nephrology and the US FDA. Her advocacy for the kidney disease trial endeavour is pursued through roles in the AKTN, the International Society of Nephrology Advancing Clinical Trials (ISN-ACTS) core committee and the ANZSN Research Advisory Committee.
Adverse Effects of SGLT2 Inhibition in Advanced Diabetic Kidney Disease and How to Minimize Them
October 22, 2020 | 11:30 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Treating the Whole Person with Diabetic Kidney Disease: New Clinical Protocols
12:00 PM - 12:30 PM
Katherine R. Tuttle, MD, FASN
Katherine R. Tuttle, MD, FASN
Katherine R. Tuttle, MD, FASN, FACP, FNKF, is Executive Director for Research at Providence Health Care, Co-Principal Investigator of the Institute of Translational Health Sciences and Professor of Medicine at the University of Washington. Dr. Tuttle earned her medical degree and completed her residency in Internal Medicine at Northwestern University School of Medicine in Chicago, Illinois. She was a fellow in Metabolism and Endocrinology at Washington University in St. Louis, Missouri. Her Nephrology fellowship training was performed at University of Texas Health Science Center in San Antonio, Texas.
Dr. Tuttle’s major research interests are in clinical and translational science for diabetes and chronic kidney disease. She has published over 200 original research contributions and served two terms each as Associate Editor for the Clinical Journal of the American Society of Nephrology and for the American Journal of Kidney Disease. Dr. Tuttle has received many honors and awards including the Medal of Excellence from the American Association of Kidney Patients, Garbed Eknoyan Award from the National Kidney Foundation, the YWCA Woman of Achievement Award in Science, and two Outstanding Clinical Faculty Awards at the University of Washington. Dr. Tuttle served on the Board of Directors for the Kidney Health Initiative and has chaired numerous kidney and diabetes related working groups and committees for organizations including the NIDDK/NIH, the National Kidney Foundation, the American Society of Nephrology, the International Society of Nephrology, and the American Diabetes Association.
Treating the Whole Person with Diabetic Kidney Disease: New Clinical Protocols
October 22, 2020 | 12:00 PM - 12:30 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
